These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11399864)

  • 1. Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice.
    Iyamu WE; Lian L; Asakura T
    Chemotherapy; 2001; 47(4):270-8. PubMed ID: 11399864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
    Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
    J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
    Jones KM; Niaz MS; Brooks CM; Roberson SI; Aguinaga MP; Hills ER; Rice VM; Bourne P; Bruce D; Archibong AE
    Int J Environ Res Public Health; 2009 Mar; 6(3):1124-44. PubMed ID: 19440437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal doses of hydroxyurea for sickle cell disease.
    Lima CS; Arruda VR; Costa FF; Saad ST
    Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
    Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
    Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
    J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of hydroxyurea.
    Gwilt PR; Tracewell WG
    Clin Pharmacokinet; 1998 May; 34(5):347-58. PubMed ID: 9592619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.
    Pressiat C; Rakotoson MG; Habibi A; Barau C; Arrouasse R; Galactéros F; Stehlé T; Audard V; Hulin A; Bartolucci P
    Br J Clin Pharmacol; 2021 May; 87(5):2274-2285. PubMed ID: 33217005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
    Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
    Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined hydroxyurea and ET
    Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
    Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
    Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management.
    Gour A; Kour D; Dogra A; Manhas D; Wazir P; Digra SK; Kumar A; Nandi U
    Toxicol Appl Pharmacol; 2022 Aug; 449():116113. PubMed ID: 35691369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
    Lopes FC; Traina F; Almeida CB; Leonardo FC; Franco-Penteado CF; Garrido VT; Colella MP; Soares R; Olalla-Saad ST; Costa FF; Conran N
    Haematologica; 2015 Jun; 100(6):730-9. PubMed ID: 25769545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.